Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2015 3
2016 3
2017 4
2018 12
2019 15
2020 16
2021 24
2022 22
2023 14
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Choueiri TK, et al. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. N Engl J Med. 2023. PMID: 37163623 Free PMC article. Clinical Trial.
Publisher Erratum zu: Digitalisierung in der Urologie – Herausforderung und Chance.
AK Informationstechnologie und Dokumentation (IT@DOC) (DGU), AK Versorgungsforschung, Qualität und Ökonomie (DGU); AK Informationstechnologie und Dokumentation (IT@DOC) (DGU); AK Versorgungsforschung, Qualität und Ökonomie (DGU); AK Bildgebende Systeme (DGU), Sektion Urologie (DEGUM); Witzsch UKF, Borkowetz A, Enzmann T, Rodler S, Leyh-Bannurah SR, Loch T, Borgmann H, Steidle O. AK Informationstechnologie und Dokumentation (IT@DOC) (DGU), AK Versorgungsforschung, Qualität und Ökonomie (DGU), et al. Among authors: borkowetz a. Urologie. 2023 Oct;62(10):1094. doi: 10.1007/s00120-023-02196-0. Urologie. 2023. PMID: 37642684 German. No abstract available.
Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis.
Schneidewind L, Kiss B, Zengerling F, Borkowetz A, Graf S, Kranz J, Dräger DL, Graser A, Bellut L, Uhlig A. Schneidewind L, et al. Among authors: borkowetz a. J Cancer Res Clin Oncol. 2023 Sep;149(11):9399-9408. doi: 10.1007/s00432-023-04788-x. Epub 2023 Apr 20. J Cancer Res Clin Oncol. 2023. PMID: 37079051 Free PMC article. Review.
[Digitalization in urology-challenge and opportunity].
AK Informationstechnologie und Dokumentation (IT@DOC) (DGU), AK Versorgungsforschung, Qualität und Ökonomie (DGU); AK Informationstechnologie und Dokumentation (IT@DOC) (DGU); AK Versorgungsforschung, Qualität und Ökonomie (DGU); AK Bildgebende Systeme (DGU), Sektion Urologie (DEGUM); Witzsch UKF, Borkowetz A, Enzmann T, Rodler S, Leyh-Bannurah SR, Loch T, Borgmann H, Steidle O. AK Informationstechnologie und Dokumentation (IT@DOC) (DGU), AK Versorgungsforschung, Qualität und Ökonomie (DGU), et al. Among authors: borkowetz a. Urologie. 2023 Sep;62(9):913-928. doi: 10.1007/s00120-023-02154-w. Epub 2023 Aug 22. Urologie. 2023. PMID: 37606658 Review. German.
A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
Rade M, Kreuz M, Borkowetz A, Sommer U, Blumert C, Füssel S, Bertram C, Löffler D, Otto DJ, Wöller LA, Schimmelpfennig C, Köhl U, Gottschling AC, Hönscheid P, Baretton GB, Wirth M, Thomas C, Horn F, Reiche K. Rade M, et al. Among authors: borkowetz a. Mol Med. 2024 Feb 1;30(1):19. doi: 10.1186/s10020-024-00789-9. Mol Med. 2024. PMID: 38302875 Free PMC article.
Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study.
Kornienko K, Siegel F, Borkowetz A, Hoffmann MA, Drerup M, Lieb V, Bruendl J, Höfner T, Cash H, von Hardenberg J, Westhoff N; GESRU Academics Prostate Cancer Group. Kornienko K, et al. Among authors: borkowetz a. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):109-116. doi: 10.1038/s41391-021-00478-2. Epub 2021 Dec 17. Prostate Cancer Prostatic Dis. 2022. PMID: 34916584 Free PMC article.
[Metastasis-directed therapy in prostate cancer].
Borkowetz A, Hölscher T. Borkowetz A, et al. Urologie. 2024 Mar;63(3):225-233. doi: 10.1007/s00120-024-02281-y. Epub 2024 Feb 22. Urologie. 2024. PMID: 38388789 Review. German.
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.
Omar MI, MacLennan S, Ribal MJ, Roobol MJ, Dimitropoulos K, van den Broeck T, MacLennan SJ, Axelsson SE, Gandaglia G, Willemse PP, Mastris K, Ransohoff JB, Devecseri Z, Abbott T, De Meulder B, Bjartell A, Asiimwe A, N'Dow J; PIONEER Consortium. Omar MI, et al. Nat Rev Urol. 2023 Aug;20(8):494-501. doi: 10.1038/s41585-023-00748-9. Epub 2023 Apr 3. Nat Rev Urol. 2023. PMID: 37012441 Review.
Risk factors for esophageal cancer in a high-incidence area of Malawi.
Geßner AL, Borkowetz A, Wilhelm TJ, Ludzu E, Baier M, Mastala Y, Nyirenda S, Mothes H. Geßner AL, et al. Among authors: borkowetz a. Cancer Causes Control. 2021 Dec;32(12):1347-1354. doi: 10.1007/s10552-021-01482-6. Epub 2021 Aug 3. Cancer Causes Control. 2021. PMID: 34342770
101 results